Brief: Aileron Therapeutics Announces Positive Topline Data From Cohort 2 Of The Phase 1B Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis
13/11/2024 13:26
Nov 13 (Reuters) - Aileron Therapeutics Inc ALRN.O :
* AILERON THERAPEUTICS ANNOUNCES POSITIVE TOPLINE DATA FROM
COHORT
2 OF THE PHASE 1B CLINICAL TRIAL OF LTI-03 IN IDIOPATHIC
PULMONARY FIBROSIS (IPF)
* AILERON THERAPEUTICS INC - HIGH-DOSE LTI-03 WELL-TOLERATED
WITH
NO SAFETY SIGNALS
* AILERON THERAPEUTICS INC - HIGH-DOSE LTI-03 REDUCES
EXPRESSION
OF PROFIBROTIC PROTEINS
Source text: urn:newsml:reuters.com:*:nPnbBFqKLa
Further company coverage: ALRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering